THC Farmaceuticals, Inc. (CBDG)
USD 0.01
(8.0%)
USD 0.01
(8.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 139.8 Thousand USD | 0.0% |
| 2022 | 139.8 Thousand USD | -60.49% |
| 2021 | 353.82 Thousand USD | 4.02% |
| 2020 | 340.13 Thousand USD | -62.79% |
| 2019 | 914.17 Thousand USD | 3.3% |
| 2018 | 885.01 Thousand USD | -3.1% |
| 2017 | 913.36 Thousand USD | 0.77% |
| 2016 | 906.36 Thousand USD | 0.0% |
| 2014 | 77.06 USD | 32.49% |
| 2013 | 58.16 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 Q3 | 379.42 Thousand USD | 1.82% |
| 2022 Q1 | 330.57 Thousand USD | 0.0% |
| 2022 Q2 | 372.63 Thousand USD | 12.72% |
| 2021 FY | 353.82 Thousand USD | 4.02% |
| 2020 FY | 340.13 Thousand USD | -62.79% |
| 2020 Q1 | 338.36 Thousand USD | 0.0% |
| 2019 FY | 914.17 Thousand USD | 3.3% |
| 2019 Q2 | 907.4 Thousand USD | 0.0% |
| 2019 Q3 | 914.69 Thousand USD | 0.8% |
| 2018 FY | 885.01 Thousand USD | -3.1% |
| 2017 FY | 913.36 Thousand USD | 0.77% |
| 2016 FY | 906.36 Thousand USD | 0.0% |
| 2015 Q3 | 678.67 USD | 968.03% |
| 2015 Q2 | 63.54 USD | 3368.56% |
| 2015 Q1 | 1.83 USD | -97.62% |
| 2014 Q1 | 60.24 USD | 3.56% |
| 2014 Q4 | 77.06 USD | 3.34% |
| 2014 FY | 77.06 USD | 32.49% |
| 2014 Q3 | 74.57 USD | 1.81% |
| 2014 Q2 | 73.25 USD | 21.6% |
| 2013 FY | 58.16 USD | 0.0% |
| 2013 Q2 | 51.67 USD | 0.0% |
| 2013 Q4 | 58.16 USD | 7.9% |
| 2013 Q3 | 53.91 USD | 4.34% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 10772.061% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 97.525% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.673% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 156.007% |
| Rebus Holdings, Inc. | 305 Thousand USD | 54.163% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 102.218% |
| Qrons Inc. | 351.42 Thousand USD | 60.218% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 77.537% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.678% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 785.045% |
| Skye Bioscience, Inc. | -5.72 Million USD | 102.444% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.113% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 96.605% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 65.21% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.386% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 93.765% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 84.922% |
| Mesoblast Limited | 55.85 Million USD | 99.75% |
| Marizyme, Inc. | 18.56 Million USD | 99.247% |
| Genus plc | 190.6 Million USD | 99.927% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 93.747% |
| Pharming Group N.V. | 109.8 Million USD | 99.873% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 83.748% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 88.483% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 79.441% |
| ContraFect Corporation | -6.02 Million USD | 102.32% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3.836% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 87.9% |
| IMV Inc. | 7.67 Million USD | 98.177% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 97.459% |
| MultiCell Technologies, Inc. | 90.04 USD | -155168.769% |
| ONE Bio Corp. | 9.04 Million USD | 98.454% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 119.047% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.92% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 89.78% |
| Q BioMed Inc. | 4.06 Million USD | 96.557% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.542% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 86.127% |
| Biomind Labs Inc. | 711.4 Thousand USD | 80.348% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.769% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 93.008% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.908% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 61.134% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -603.7% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 93.651% |
| GB Sciences, Inc. | 1.74 Million USD | 91.999% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 176.068% |
| HST Global, Inc. | 96.79 Thousand USD | -44.436% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 32.205% |
| Halberd Corporation | 144.72 Thousand USD | 3.398% |
| Enzolytics Inc. | 981.65 Thousand USD | 85.758% |
| Agentix Corp. | 37.63 Thousand USD | -271.513% |
| Resverlogix Corp. | 6.45 Million USD | 97.833% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 120.771% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.007% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.297% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.023% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.839% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 101.582% |
| AVAX Technologies, Inc. | -5.9 Million USD | 102.368% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1289.149% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.013% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 30.249% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 94.141% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 15.017% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 863.206% |
| Kadimastem Ltd | -253.1 Thousand USD | 155.236% |
| Helix BioMedix, Inc. | -2.57 Million USD | 105.44% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.31% |
| BioStem Technologies, Inc. | 4.47 Million USD | 96.874% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 30.534% |
| LadRx Corporation | -2.03 Million USD | 106.865% |
| Cell Source, Inc. | 9.23 Million USD | 98.486% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 77.989% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 77.989% |
| NovAccess Global Inc. | 2.17 Million USD | 93.582% |
| Affymax, Inc. | -5.59 Million USD | 102.498% |
| Itoco Inc. | 228.3 Thousand USD | 38.764% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2.805% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 97.18% |
| Mobile Lads Corp. | 484.23 Thousand USD | 71.129% |
| CytoDyn Inc. | 20.26 Million USD | 99.31% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 21708.037% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1608.404% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.186% |
| SYBLEU INC | 473.71 Thousand USD | 70.488% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 96.863% |
| International Stem Cell Corporation | 2.59 Million USD | 94.602% |
| Bioxytran, Inc. | 1.89 Million USD | 92.638% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -123.998% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.59% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 95.929% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.365% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 81.905% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 111.184% |
| Neutra Corp. | 52.18 Thousand USD | -167.89% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 105.617% |
| PureTech Health plc | -167.19 Million USD | 100.084% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 157.084% |
| IXICO plc | -4.44 Million USD | 103.145% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.942% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.745% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.319% |